[HTML][HTML] Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma
The incidence of melanoma is increasing worldwide. Advances in targeted agents and
immunotherapy have improved outcomes in metastatic disease, but biomarkers are required …
immunotherapy have improved outcomes in metastatic disease, but biomarkers are required …
Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma.
L Khoja, PC Lorigan, C Zhou, M Lancashire, J Booth… - 2012 - christie.openrepository.com
The incidence of melanoma is increasing worldwide. Advances in targeted agents and
immunotherapy have improved outcomes in metastatic disease, but biomarkers are required …
immunotherapy have improved outcomes in metastatic disease, but biomarkers are required …
Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma
L Khoja, P Lorigan, C Zhou… - The Journal of …, 2013 - pubmed.ncbi.nlm.nih.gov
The incidence of melanoma is increasing worldwide. Advances in targeted agents and
immunotherapy have improved outcomes in metastatic disease, but biomarkers are required …
immunotherapy have improved outcomes in metastatic disease, but biomarkers are required …
Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma.
L Khoja, P Lorigan, C Zhou… - Journal of …, 2013 - search.ebscohost.com
The incidence of melanoma is increasing worldwide. Advances in targeted agents and
immunotherapy have improved outcomes in metastatic disease, but biomarkers are required …
immunotherapy have improved outcomes in metastatic disease, but biomarkers are required …
Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma
L Khoja, P Lorigan, C Zhou… - The Journal of …, 2013 - research.manchester.ac.uk
The incidence of melanoma is increasing worldwide. Advances in targeted agents and
immunotherapy have improved outcomes in metastatic disease, but biomarkers are required …
immunotherapy have improved outcomes in metastatic disease, but biomarkers are required …
[PDF][PDF] Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma
L Khoja, P Lorigan, C Zhou, M Lancashire… - Journal of Investigative …, 2013 - academia.edu
Melanoma is the most serious form of skin cancer and the incidence is increasing
worldwide. Approximately 80% of patients are cured with surgery. The prognosis of patients …
worldwide. Approximately 80% of patients are cured with surgery. The prognosis of patients …
[引用][C] Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma
L Khoja, P Lorigan, C Zhou, M Lancashire… - Journal of Investigative …, 2013 - cir.nii.ac.jp
Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
[PDF][PDF] Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma
L Khoja, P Lorigan, C Zhou… - Journal of …, 2013 - scholar.archive.org
Melanoma is the most serious form of skin cancer and the incidence is increasing
worldwide. Approximately 80% of patients are cured with surgery. The prognosis of patients …
worldwide. Approximately 80% of patients are cured with surgery. The prognosis of patients …
[PDF][PDF] Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma
L Khoja, P Lorigan, C Zhou, M Lancashire… - Journal of Investigative …, 2013 - core.ac.uk
Melanoma is the most serious form of skin cancer and the incidence is increasing
worldwide. Approximately 80% of patients are cured with surgery. The prognosis of patients …
worldwide. Approximately 80% of patients are cured with surgery. The prognosis of patients …